NCT03594604 is a Phase 4 clinical trial of Norethindrone in Menstrual Flow Altered, sponsored by Wayne State University.

Who is sponsoring NCT03594604?

NCT03594604 is sponsored by Wayne State University.

What drugs are being tested in NCT03594604?

Interventions in NCT03594604: Norethindrone, oral contraceptive pill.

What condition does NCT03594604 study?

NCT03594604 studies Menstrual Flow Altered.

Is NCT03594604 still recruiting?

NCT03594604 is currently completed. Last updated 20 July 2018.

Last reviewed 2018-07-20 · How we verify

NCT03594604

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Norethindrone for the Delay of Menstruation

Completed Phase 4 Last updated 20 July 2018

What this trial tests

Phase 4 trial testing Norethindrone in Menstrual Flow Altered in 17 participants. Completed in 15 December 2007.

Timeline

15 June 2007

Primary endpoint
15 December 2007

15 December 2007

Quick facts

Lead sponsor	Wayne State University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	17
Start date	15 June 2007
Primary completion	15 December 2007
Estimated completion	15 December 2007

Drugs / interventions tested

Norethindrone — full drug profile →
oral contraceptive pill — full drug profile →

Conditions studied

Menstrual Flow Altered — all drugs for Menstrual Flow Altered →

Sponsor

Wayne State University

Who can join

Adults 18 to 45, female only, with Menstrual Flow Altered. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of oral contraceptive pills versus norethindrone to delay menstuation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Norethindrone is superior to combined oral contraceptive pills in short-term delay of menses and onset of breakthrough bleeding: a randomized trial.
Dean J, Kramer KJ, Akbary F, Wade S, et al · · 2019 · cited 10× · PMID 31138184 · DOI 10.1186/s12905-019-0766-6

Verify or expand the search:

Other Wayne State University trials

Trials by the same sponsor.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03594604 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wayne State University
Last refreshed: 20 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03594604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing